Cargando…
Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review
DeltaRex-G is a replication-incompetent amphotropic murine leukemia virus-based retroviral vector that displays a collagen-matrix-targeting decapeptide on its surface envelope protein, gp70, and encodes a cytocidal ‘dominant negative’, i.e. a truncated construct of the executive cyclin G1 (CCNG1) on...
Autores principales: | Morse, Michael A., Chawla, Sant P., Wong, Terence Z., Bruckner, Howard W., Hall, Frederick L., Gordon, Erlinda M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278409/ https://www.ncbi.nlm.nih.gov/pubmed/34277005 http://dx.doi.org/10.3892/mco.2021.2348 |
Ejemplares similares
-
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
por: Chawla, Sant P., et al.
Publicado: (2018) -
Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report
por: Kim, Seth, et al.
Publicado: (2017) -
Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists
por: Gordon, Erlinda M., et al.
Publicado: (2018) -
Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
por: Al-Shihabi, Ahmad, et al.
Publicado: (2018) -
Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
por: Chawla, Sant P, et al.
Publicado: (2009)